TCRX vs. OCGN, LXEO, CCCC, REPL, VYGR, EDIT, FATE, TSHA, SLDB, and AURA
Should you be buying TScan Therapeutics stock or one of its competitors? The main competitors of TScan Therapeutics include Ocugen (OCGN), Lexeo Therapeutics (LXEO), C4 Therapeutics (CCCC), Replimune Group (REPL), Voyager Therapeutics (VYGR), Editas Medicine (EDIT), Fate Therapeutics (FATE), Taysha Gene Therapies (TSHA), Solid Biosciences (SLDB), and Aura Biosciences (AURA). These companies are all part of the "biological products, except diagnostic" industry.
TScan Therapeutics (NASDAQ:TCRX) and Ocugen (NASDAQ:OCGN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, community ranking, valuation, media sentiment, profitability and risk.
Ocugen has lower revenue, but higher earnings than TScan Therapeutics. Ocugen is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.
Ocugen has a net margin of 0.00% compared to TScan Therapeutics' net margin of -653.50%. TScan Therapeutics' return on equity of -61.13% beat Ocugen's return on equity.
Ocugen received 79 more outperform votes than TScan Therapeutics when rated by MarketBeat users. However, 74.19% of users gave TScan Therapeutics an outperform vote while only 68.92% of users gave Ocugen an outperform vote.
TScan Therapeutics has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500. Comparatively, Ocugen has a beta of 3.49, suggesting that its stock price is 249% more volatile than the S&P 500.
In the previous week, TScan Therapeutics had 15 more articles in the media than Ocugen. MarketBeat recorded 39 mentions for TScan Therapeutics and 24 mentions for Ocugen. Ocugen's average media sentiment score of 0.43 beat TScan Therapeutics' score of -0.10 indicating that Ocugen is being referred to more favorably in the news media.
82.8% of TScan Therapeutics shares are held by institutional investors. Comparatively, 10.3% of Ocugen shares are held by institutional investors. 2.8% of TScan Therapeutics shares are held by insiders. Comparatively, 3.5% of Ocugen shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
TScan Therapeutics currently has a consensus price target of $12.00, indicating a potential upside of 33.63%. Ocugen has a consensus price target of $4.67, indicating a potential upside of 144.33%. Given Ocugen's higher probable upside, analysts plainly believe Ocugen is more favorable than TScan Therapeutics.
Summary
Ocugen beats TScan Therapeutics on 9 of the 17 factors compared between the two stocks.
Get TScan Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TCRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
TScan Therapeutics Competitors List
Related Companies and Tools
